Behfar Ehdaie, MD, MPH, presented “Role of MR-Targeted Prostate Biopsy in Active Surveillance” virtually during the Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on October 8th, 2020.
How to cite: Ehdaie, Behfar. “Role of MR-Targeted Prostate Biopsy in Active Surveillance” October 8th, 2020. Accessed Dec 2024. https://dev.grandroundsinurology.com/role-of-mr-targeted-prostate-biopsy-in-active-surveillance/
Summary:
Behfar Ehdaie, MD, MPH, a urologic surgeon at Memorial Sloan Kettering Cancer Center, discusses how MR-targeted prostate biopsy in active surveillance improves detection of higher grade prostate cancer and reduces misclassification of patients with low-risk disease. He summarizes the findings of studies that demonstrate MR-targeted biopsy’s superiority over systematic biopsy in detecting cancer, the particular benefits of MR-ultrasound software fusion prostate biopsy as compared to visually targeted biopsy, and the importance of combining MR-targeted biopsy with systematic biopsy since some tumors are not visible on MRI. Dr. Ehdaie also notes that patients on active surveillance particularly benefit from scheduled MR-targeted biopsies since only using changes in surveillance MRI and clinical stage to trigger biopsy can cause many higher grade cancers to be missed. Dr. Ehdaie concludes by emphasizing the importance of using a transperineal biopsy technique as opposed to a transrectal one in order to reduce complications and improve cancer detection.
The Virtual Global Summit on Precision Diagnosis and Treatment of Prostate Cancer brings together key international opinion leaders of every clinical subspecialty involved in patient care. This event is an integral part of the AdMeTech Foundation’s Annual Summit, which was established in 2016 and became seminal in shaping the state of the art and future vision for precision care. The goal of this event is three-fold: 1) Educating the key stakeholders; 2) Supporting a sustained cross-disciplinary dialogue and consensus on the best emerging clinical practices and research priorities; and 3) Expediting clinical adoption of promising novel diagnostics and therapeutics. Dr. Ehdaie presented this on the second day of the conference. For more educational activities from this virtual event, visit our collection page.
ABOUT THE AUTHOR
Behfar Ehdaie, MD, MPH, is a urologic surgeon at Memorial Sloan Kettering Cancer Center in New York City. He earned his medical degree at Georgetown University School of Medicine and then went on to a urology residency at the University of Virginia School of Medicine and a fellowship at Memorial Sloan Kettering Cancer Center. Dr. Ehdaie is an expert in minimally invasive surgical techniques for the treatment of urologic cancers, and has a particular interest in novel management of prostate cancer, kidney tumors, and bladder cancer. He has performed more than 500 MRI-guided prostate biopsies and is experienced in doing extensive lymph node removals at the time of prostate surgery. His research is focused on achieving prostate cancer cures while also preserving quality of life, and he is currently the principal investigator on a clinical trial of partial gland ablation that theoretically could allow patients with prostate cancer to receive effective treatment minus side effects like incontinence and erectile dysfunction. Dr. Ehdaie also aims to improve active surveillance by developing a large surveillance clinic that will use advanced imaging and biomarkers to detect cancer progression. Dr. Ehdaie has given presentations on prostate cancer throughout the United States and around the world, and has also published numerous articles and studies in peer-reviewed journals.
